Gastroesophageal reflux disease: From heartburn to cancer
- PMID: 20698034
- PMCID: PMC2921083
- DOI: 10.3748/wjg.v16.i30.3743
Gastroesophageal reflux disease: From heartburn to cancer
Abstract
About 10%-15% of patients with gastroesophageal reflux disease develop Barrett's esophagus. This is considered a premalignant condition because it can progress from metaplasia to high-grade dysplasia, and eventually to adenocarcinoma. Recently, major advances have been made in the endoscopic treatment of Barrett's esophagus, therefore limiting the role of surgery in the treatment of this disease.
References
-
- Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511. - PubMed
-
- Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146. - PubMed
-
- Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet. 1997;350:933. - PubMed
-
- Kahrilas PJ. Anatomy and physiology of the gastroesophageal junction. Gastroenterol Clin North Am. 1997;26:467–486. - PubMed
-
- Herbella FA, Sweet MP, Tedesco P, Nipomnick I, Patti MG. Gastroesophageal reflux disease and obesity. Pathophysiology and implications for treatment. J Gastrointest Surg. 2007;11:286–290. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
